FDA Singles Out Three Drug Substances to Not be Compounded

Regulatory Focus-10 hours ago

Vasopressin, meanwhile, is the active ingredient in Vasostrict, and was the subject of Endo's lawsuit over how the FDA regulates drug compounding.

Par Wants Bulk Vasopressin Compounding Nixed; FDA Agrees
Law360-1 hour ago

FDA proposes restricting compounding of three drug substances
Reuters-10 hours ago

US FDA proposes restricting compounding of 3 drug substances
Thomson Reuters Foundation-10 hours ago

FDA Says No Need to Compound from Bumetanide, Nicardipine ...
Pharmaceutical Technology Magazine-7 hours ago

View all